<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3310">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02060201</url>
  </required_header>
  <id_info>
    <org_study_id>CV181-341</org_study_id>
    <nct_id>NCT02060201</nct_id>
  </id_info>
  <brief_title>Bioequivalence/Food Effect - Saxa/Dapa Dual Fixed Dose Combination (FDC)</brief_title>
  <official_title>A Bioequivalence Study of 2.5-mg Saxagliptin/5-mg Dapagliflozin and 5-mg Saxagliptin/10-mg Dapagliflozin Fixed Dose Combination Tablets Relative to Coadministration of Their Respective Individual Components in Healthy Subjects and a Characterization of the Effect of Food on the Fixed Dose Combination Tablets</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate the bioequivalence (BE) of Saxagliptin and
      Dapagliflozin from a 2.5-mg Saxagliptin/5-mg Dapagliflozin FDC tablet after oral
      administration relative to 2.5-mg Saxagliptin and 5-mg Dapagliflozin tablets administered
      orally together in the fasted state and to demonstrate the BE of Saxagliptin and
      Dapagliflozin from a 5-mg Saxagliptin/10-mg Dapagliflozin FDC tablet after oral
      administration relative to 5-mg Saxagliptin and 10-mg Dapagliflozin tablets administered
      orally together in the fasted state.  Demonstrating bioequivalence refers to showing that
      the FDC tablet and co-administration of the individual components yield similar blood
      levels/concentrations of the drug and are handled by the body similarly.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Primary Purpose: This study is designed to demonstrate the bioequivalence of Saxagliptin and
      Dapagliflozin from a FDC tablet after oral administration relative to Saxagliptin and
      Dapagliflozin tablets administered orally together in the fasted and fed state
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Crossover Assignment, Masking: Open Label</study_design>
  <primary_outcome>
    <measure>Maximum observed plasma concentration (Cmax) for Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero to the time of the last quantifiable concentration [(AUC(0-T)] for Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve from time zero extrapolated to infinite time [(AUC(INF)] for Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax for 5-hydroxy (OH) Saxagliptin</measure>
    <time_frame>54 time points up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(0-T) for 5-hydroxy (OH) Saxagliptin</measure>
    <time_frame>54 time points up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC(INF) for 5-hydroxy (OH) Saxagliptin</measure>
    <time_frame>54 time points up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent of AUC extrapolated from last quantifiable concentration to infinity (pAUCe) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half life (T HALF) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Terminal disposition rate constant (Lambda) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time point where log-linear elimination begins (TLIN) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time at which the last concentration occurred that is above the lower limit of quantitation (LQCT) for Saxagliptin, 5-OH Saxagliptin and Dapagliflozin</measure>
    <time_frame>54 time points for Saxagliptin, 5-OH Saxagliptin and 42 time points for Dapagliflozin up to 15 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety measured by the occurrence of deaths, adverse events (AEs), serious adverse events (SAEs), results of clinical laboratory tests, vital sign measurements, physical examination findings, and 12-lead electrocardiogram (ECG) results</measure>
    <time_frame>Approximately up to 16 days</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">72</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saxagliptin 2.5 mg tablet and Dapagliflozin 5 mg tablet single dose orally on Day 1 in one of 3 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saxagliptin 2.5 mg/Dapagliflozin 5 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saxagliptin 5 mg tablet and Dapagliflozin 10 mg tablet single dose orally for on Day 1 in one of 3 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Saxagliptin 5 mg/Dapagliflozin 10 mg fixed dose combination tablet single dose orally on Day 1 in one of 3 periods</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin</intervention_name>
    <arm_group_label>Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting</arm_group_label>
    <arm_group_label>Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting</arm_group_label>
    <other_name>Onglyza®</other_name>
    <other_name>BMS-477118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dapagliflozin</intervention_name>
    <arm_group_label>Treatment A: Saxagliptin 2.5mg+Dapagliflozin 5mg; Fasting</arm_group_label>
    <arm_group_label>Treatment D: Saxagliptin 5mg+Dapagliflozin 10mg; Fasting</arm_group_label>
    <other_name>Farxiga®</other_name>
    <other_name>Forxiga®</other_name>
    <other_name>BMS-512148</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Saxagliptin/Dapagliflozin FDC</intervention_name>
    <arm_group_label>Treatment B: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fasting</arm_group_label>
    <arm_group_label>Treatment C: Saxagliptin 2.5mg/Dapagliflozin 5mg FDC; Fed</arm_group_label>
    <arm_group_label>Treatment E: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fasting</arm_group_label>
    <arm_group_label>Treatment F: Saxagliptin 5mg/Dapagliflozin 10mg FDC; Fed</arm_group_label>
    <other_name>BMS-986098</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy subjects as determined by no clinically significant deviation from normal in
             medical history, physical examination (PE), vital signs, 12-lead ECG, and clinical
             laboratory determinations

          -  Body mass index (BMI) of 18.5 to 30 kg/m(2)

          -  Men and women, ages 18 to 50 years

          -  Women of childbearing potential must use acceptable methods of highly effective birth
             control

        Exclusion Criteria:

          -  Any significant acute or chronic medical illness

          -  Current or recent gastrointestinal disease

          -  Any major surgery within 4 weeks of study drug administration

          -  History of chronic or recurrent urinary tract infection for females

          -  History of glucose intolerance or diabetes mellitus

          -  History of allergies or adverse reactions to Dipeptidyl peptidase-IV (DPP4) or
             Sodium-glucose cotransporter (SGLT) inhibitors

          -  Prior exposure to Saxagliptin or Dapagliflozin or related drugs
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 10, 2014</lastchanged_date>
  <firstreceived_date>February 10, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Saxagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
